One of the key strategies in epigenetic therapy involves the use of DNA methyltransferase (DNMT) inhibitors, which work by blocking the activity of DNMT enzymes responsible for adding methyl groups to specific DNA sequences, thereby leading to the reactivation of tumor suppressor genes that were silenced through aberrant DNA methylation. This evidence concerns the gene DNMT1 and neoplasm.